Member Info for Johnny1949

Lombard O still selling into re spud rise ....

TR1 saying Lombard sold 0.55% of the company up ton3/8/2019 probably still selling into anticipated rise ...hence the sp fall with the chunky sells ....

Lombard Odier TR1 selling ...

Looks like an II selling ,could it be SVS ....?

RNS should demonstrate large revenue increases , and with restructuring together with sale of loss making arm , there is much fairer financial water ahead so definitely a buy 8p target maybe in 6 months multibagger , AND , relatives of the board buying !

Very positive RNS definitely hinting that a J/V with a major pharma ,for sale of Iclaprim ,or marketing of Iclaprim, is close ,the appointment of a specialist in this area obviously of great importance ,no point in an appointment if the drug is not marketable .Also indicating that at least one other larger pharma agrees and sees commercial opportunity imo

Looks like T/o or J/V maybe this has been on the cards for the last few months and could be the “non public “ reason for the FDA response ...strong possibility ,otherwise why the specialised appointment ?

Basically there appears very little reason not to allow use of this new antibiotic for skin infections ,indeed it is marginally better and has fewer side effects than Vancomycin....I have always questioned the failure of the FDA to pass the clinical trials as the organisation know this drug and I can only wonder if there is something not in the public arena which is causing this situation ...however in the past having been involved in new drug trials and submissions I am dumbfounded that Iclaprim has not been passed for use in skin infections where new antibiotics are sorely needed ...

Great RNS we are up and running ,just got to sit on hands and wait for the re rating ,Miles needs around 15p to be in pocket but my guess he wants a lot more ....

I’m not aware of any serious liver issues from the trial results ,many drugs result in mild elevation of liver enzymes for various reasons ,and I wonder do the FDA want mor evidence on the mechanism of liver disturbance as if the mechanism is known the real result of apparent liver disturbance can be extrapolated to be non toxic or toxic .....imo

Lombard don’t take 25% to lose money this share will fly and Miles will make very serious money ,I’m loaded and waiting !

Just a wait now FDA interested but not ready to approve just yet ,antibiotics badly needed ....

Watch this company revenue could be massive

In my opinion the drug is very close to approval ...but in 2 studies comparison with vancomycin revealed a few more patients with raised liver function tests in the Iclaprim group ...these results on their own seem lnsignificant ,but the FDA may need some clarification on the specific patients affected such as previous medical history for example but it is possible that a demand for a short further study may be required ...we have to wait and see .a large number of drugs do cause transient liver function test abnormalities ...with some past experience in drug research I would have thought a qualified approval with liver function test monitoring might be appropriate ...but it’s not a given ..

Thoth as a doctor I can say you are completely wrong in your last 2 posts either from a complete lack of knowledge or from a deliberate decamp so as to get an entry ....sorry but there is a massive market for anti Staphlococcus drugs particularly ones with little toxicity for skin infections in diabetes ...9% of the nhs budget goes to diabetes and much of this is spent in either treating infected (staphloccal) leg ulcers which can very rapidly progress to amputation ..at a cost of 50k and with a high risk of amputation of the other limb in 5 years ...please go and infect another board or else dont show your complete ignorance of medicine ,,,

Glad to see the Matadors are alive and well ,this could finally be our year !

Hell of a lot of buys at this price ,there is still belief in this company ....but I wish the company would support the investors with more accurate information ..

This company is in the right place at the right time ,antibiotics are a Government priority ,they will pump money into research ,especially an antibiotic that kills staphlococcus ,this share should multibag in the next few months provided phase11b goes well which I expect it will with the array of talent in the company ...watch this share!

It looks like Lombard Odier are convinced .....

Another 250k buy today ....will we see another tr1 ? Must be due some sp action soon ....